Vanessa joined Forbion in 2022 and is currently a Principal. She focuses on driving investments and company building efforts across various therapeutic areas and modalities.
Vanessa currently serves as a director on the boards of Elevara Medicines, Gate Bioscience, and VectorY Therapeutics and holds observer positions on the boards of Orbis Medicines, Rathlin, and Sitala Bio. Previously, Vanessa played a key role in leading due diligence and was a board observer for Mariana Oncology (acquired by Novartis in 2024), and AIRNA.
Before joining Forbion, Vanessa was at PharmaVentures, where she focused on transaction advisory and corporate strategy projects. Earlier in her career, she worked as a scientist and co-Principal Investigator at the Swiss Federal Institute of Technology Lausanne (EPFL), contributing to a translational drug development project.
Vanessa holds a BSc in Biotechnology from the University of Pavia (Italy), an MSc in Pharmaceutical Biotechnology from Martin Luther University Halle-Wittenberg (Germany), and a PhD in Chemical Biology from EPFL (Switzerland).
At Forbion, I have the opportunity to help shape the future of biotech by partnering with exceptional companies and founders to drive bold ideas forward. What excites me most is the ability to take real ownership across the investment lifecycle—from scientific diligence and deal execution to taking board roles and actively supporting companies post-investment. The entrepreneurial and collaborative culture at Forbion empowers me to contribute meaningfully and operate with autonomy, while being part of a deeply experienced team united by a shared commitment to advancing science and improving patient outcomes."
Portfolio
Companies worked on by Vanessa Carle
